# MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing

> **NCT02006069** · NA · TERMINATED · sponsor: **Abbott Medical Devices** · enrollment: 5850 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DEVICE:** MPP

## Key facts

- **NCT ID:** NCT02006069
- **Lead sponsor:** Abbott Medical Devices
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-12
- **Primary completion:** 2021-05-30
- **Final completion:** 2021-05-30
- **Target enrollment:** 5850 (ACTUAL)
- **Why stopped:** The steering committee had decided to discontinue enrollment because the interim analysis showed a low probability that the study would meet the primary endpoint. The interim analysis did not demonstrate any safety concerns with activating MPP.
- **Last updated:** 2023-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02006069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02006069, "MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02006069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*